A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2017
At a glance
- Drugs KUR-113 (Primary)
- Indications Fracture
- Focus Therapeutic Use
- Sponsors Kuros Biosurgery
- 20 Jan 2016 Primary endpoint 'Proportion of patients healed 6 months after the surgery' has been met, according to a Kuros Biosciences media release.
- 10 Jul 2012 New source identified and integrated: ClinicalTrials.gov record NCT00533793.
- 04 Jul 2012 New trial record